Company Tagline
Jalon Therapeutics aims to develop innovative therapies that inactivate yet untargeted vital tumor signaling pathways.
Industry Category
Business Keywords
Company Description
Jalon Therapeutics is a pioneering biotechnology research company dedicated to developing innovative therapies that target and inactivate vital tumor signaling pathways. With a focus on transforming the lives of people fighting cancer, Jalon Therapeutics leverages a deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype, offering potential novel, safer, and more effective therapeutic strategies.
Located at 27, Rue Juliette Dodu, Paris, Île-de-France 75010, FR, Jalon Therapeutics is committed to advancing cancer treatment through groundbreaking research and clinical investigations. The company’s first-in-class lead candidate, JRT39, derived from AAC-11 (Anti-Apoptosis Clone-11), is designed for the treatment of hard-to-treat cancers, combining broad tissue distribution and cell permeability with excellent specificity and target-engagement potency.
Jalon Therapeutics is also building a robust drug discovery platform to develop additional candidates derived from AAC-11 and its partners. Jalon Therapeutics aims to provide breakthrough discoveries for treating advanced and refractory cancers, either alone or in combination with other treatment modalities. We invite the manager of Jalon Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight their innovative work.
Jalon Therapeutics est une entreprise de recherche en biotechnologie pionnière qui se consacre au développement de thérapies innovantes ciblant et inactivant les voies de signalisation tumorales vitales. En mettant l'accent sur la transformation de la vie des personnes luttant contre le cancer, Jalon Therapeutics exploite une compréhension approfondie des réseaux d'interaction protéine-protéine liés au stress qui maintiennent le phénotype malin, offrant ainsi des stratégies thérapeutiques potentielles novatrices, plus sûres et plus efficaces.
Située au 27, Rue Juliette Dodu, Paris, Île-de-France 75010, FR, Jalon Therapeutics s'engage à faire progresser le traitement du cancer grâce à des recherches et des études cliniques révolutionnaires. Le principal candidat de l'entreprise, JRT39, dérivé d'AAC-11 (Anti-Apoptosis Clone-11), est conçu pour le traitement des cancers difficiles à traiter, combinant une large distribution tissulaire et une perméabilité cellulaire avec une excellente spécificité et une forte puissance d'engagement de la cible.
Jalon Therapeutics met également en place une plateforme de découverte de médicaments robuste pour développer d'autres candidats dérivés d'AAC-11 et de ses partenaires. Jalon Therapeutics vise à fournir des découvertes révolutionnaires pour le traitement des cancers avancés et réfractaires, seuls ou en association avec d'autres modalités de traitement. Nous invitons le responsable de Jalon Therapeutics à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme afin de mettre davantage en valeur leur travail innovant.
Key Personnel / Employees
Compare Companies Side by Side
Compare Jalon Therapeutics with 3 companies in Biotechnology-Research
| Comparison Field |
Jalon TherapeuticsMain Company |
formerly HelomicsView Profile |
PathAIView Profile |
QuantoriView Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 1995 | 2016 | 2018 |
|
Company Size
|
— | 11-50 | 501-1,000 | 501-1,000 |
|
City
|
Paris, Île-de-France | Pittsburgh, Pennsylvania | Boston, Massachusetts | Cambridge, Massachusetts |
|
Country
|
France | United States | United States | United States |
|
Skills & Keywords
Comparing with main company
|
18 Total Skills
Biotechnology
Cancer Therapies
Tumor Signaling
Drug Discovery
Clinical Research
Protein Interaction
Oncology
cancer research
first-in-class lead candidate
clinical investigations
non-oncogene addiction
drug discovery
R&D
fundamental research
develop medicines
breakthrough discovery to treat advanced & refractory cancers
stress-related protein-protein interaction networks
fight against cancer
|
18 Total
18 Unique
Unique Skills:
AI
assays
biobank of tumor samples
biomarker development
Biomarker Testing
Cancer Therapeutics
+12
|
20 Total
20 Unique
Unique Skills:
AI
artificial intelligence
auto immune disease
Clinical development
companion diagnostics
computational pathology
+14
|
21 Total
21 Unique
Unique Skills:
algorithms
clinical trial design
cloud computing
computer software
covid-19
data analytics
+15
|
4
Total Companies1995
Oldest Founded2
Countries73
Unique SkillsSimilar Companies
Other organizations in the same industry
Geneoscopy
Biotechnology-ResearchCancer Prevention | Diagnostics | Precision Medicine
Longevity Biotech Fellowship
Biotechnology-ResearchA non-profit community for people to build, join, or invest in revolutionary longevity biotechnology...
Alternative Company Names
This company is also known as